Similarly, it was reported that NSCLC patients with non-small cell lung cancer (NSCLC) who exhibit elevated baseline levels of interferon-gamma (IFN-γ) in their peripheral blood exhibit prolonged progression-free survival (PFS) upon treatment with PD-1 inhibitors [449]. This evidence concerns the gene PDCD1 and non-small cell lung carcinoma.